Get the Stockscreener App
125.92
0.21%
-0.26
After Hours:
125.92
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $125.92, with a volume of 4.26M.
It is down -0.21% in the last 24 hours and up +3.85% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$126.18
Open:
$126.42
24h Volume:
4.26M
Relative Volume:
0.70
Market Cap:
$218.96B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
15.79
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
+1.39%
1M Performance:
+3.85%
6M Performance:
-5.48%
1Y Performance:
+10.21%
1-Day Range:
$125.23
$127.14
1-Week Range:
$122.50
$129.46
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
125.92 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.54 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.53 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories stock (ABT) in focus: Exact Sciences vote date lands as earnings week nears - TechStock²
Abbott Laboratories stock drifts into earnings after Canada widens Libre 3 Plus coverage - TechStock²
Bernstein Raises Price Target for Abbott Laboratories (ABT) to $154 | ABT Stock News - GuruFocus
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $152 From $157, Maintains Buy Rating - marketscreener.com
RBC Capital Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $147 - 富途牛牛
Assessing Abbott Laboratories (ABT) Valuation After Libre Assist Expands Its Digital Diabetes Offering - Yahoo Finance
A Look At Abbott Laboratories (ABT) Valuation After Libre Assist AI Diabetes Feature Launch - simplywall.st
Is Abbott Laboratories stock protected from inflationJuly 2025 Trade Ideas & Safe Entry Momentum Stock Tips - ulpravda.ru
February 27th Options Now Available For Abbott Laboratories (ABT) - Nasdaq
Exact Sciences: Abbott Acquisition A Positive Sign For Oncology Diagnostics (NASDAQ:EXAS) - Seeking Alpha
Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Steady Multi‑Year Returns - simplywall.st
17-year Abbott employee sues, alleges firing over approved FMLA use - HRD America
Abbott: Not Cheap, But Built To Compound In Uncertain Markets (NYSE:ABT) - Seeking Alpha
Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy - The Globe and Mail
Abbott’s $105 Bid Put Exact Sciences Back In Play - Finimize
Abbott Laboratories' Fair Value Estimate Unchanged at $122 Per Share - Morningstar
Abbott’s New Libre Assist AI Tool Might Change The Case For Investing In Abbott Laboratories (ABT) - simplywall.st
Abbott Laboratories (NYSE:ABT) Given New $144.00 Price Target at Evercore ISI - MarketBeat
Should Abbott’s AI-Powered Libre Assist Shift Its Diabetes Platform Strategy Narrative for ABT Investors? - Yahoo Finance
Hematology Market Booming with Rapid Growth Through 2033 | - openPR.com
Abbott Laboratories $ABT Shares Sold by Commonwealth Equity Services LLC - MarketBeat
Abbott (ABT) Rises Higher Than Market: Key Facts - Yahoo Finance
Abbott unveils new FreeStyle Libre app feature for mealtime decisions - MassDevice
How to listen as Abbott breaks down its latest quarterly results Jan. 22 - Stock Titan
In wake of Minnesota fraud, Abbott directs investigation into childcare programs - TPI Media Group
Abbott Laboratories Stock Gains Momentum from AI and Analyst Confidence - AD HOC NEWS
Abbott Laboratories (NYSE:ABT) Price Target Raised to $169.00 - MarketBeat
Railway Pension Investments Ltd Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Healthcare Weight In S&P 500 Chart - Kalkine Media
Synergy Asset Management LLC Sells 40,094 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Acquired by Asset Management One Co. Ltd. - MarketBeat
2 Healthcare Stocks to Buy in a Bear Market - The Globe and Mail
JARISLOWSKY FRASER Ltd Has $289.05 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Has A Rock Solid Balance Sheet - 富途牛牛
Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT) - simplywall.st
Tectonic Advisors LLC Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
The Truth About Abbott Laboratories: Is This ‘Boring’ Stock Actually a Secret Power Play? - AD HOC NEWS
Top 2 Health Care Stocks That May Crash In Q1 - Benzinga
Allspring Global Investments Holdings LLC Acquires 69,578 Shares of Abbott Laboratories $ABT - MarketBeat
Bank Pictet & Cie Europe AG Has $9.82 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature - FinancialContent
Ninety One SA PTY Ltd Takes $1.49 Million Position in Abbott Laboratories $ABT - MarketBeat
Mather Group LLC. Raises Position in Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Acquires 20,035 Shares of Abbott Laboratories $ABT - MarketBeat
With EPS Growth And More, Abbott Laboratories (NYSE:ABT) Makes An Interesting Case - Yahoo Finance
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings? - TradingView — Track All Markets
The Truth About Abbott Laboratories: Viral Hype Or Boring Boomer Stock You’re Sleeping On? - AD HOC NEWS
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
Shum Financial Group Inc. Acquires Shares of 8,127 Abbott Laboratories $ABT - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 245,400 Shares of Abbott Laboratories $ABT - MarketBeat
Brendel Financial Advisors LLC Sells 23,978 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):